CASP3 and neoplasm: For instance, Raninga et al. [71] demonstrated that marizomib (Mzb), a proteasome inhibitor, inhibits complex II, which leads to reduced OXPHOS, induces caspase-3 dependent apoptosis and reduce tumor growth in TNBC, and reduces metastases in lung and brain cancers [71].